[KR-바이오] 07/02 Korea Market Insights

The decision by the Samsung Biologics labor union to withdraw from the Samsung Group-wide Union (a coalition of various Samsung affiliate unions) and pursue an independent path is a significant development in the company’s labor-management relations.

From an equity analyst’s perspective, this move introduces a degree of uncertainty regarding future collective bargaining dynamics. While the high approval rate (96%) for the withdrawal suggests strong internal cohesion, the shift toward an independent strategy may lead to more localized and potentially aggressive wage or benefit negotiations. However, as Samsung Biologics continues to maintain robust operational momentum and high capacity utilization, the immediate impact on production stability is expected to be minimal. We will monitor whether this transition leads to increased labor costs or if it serves as a mechanism for more efficient, company-specific communication.

Celltrion is strategically pivoting toward high-growth therapeutic areas and strengthening its R&D ecosystem to secure long-term competitiveness.

1. **Next-Generation Obesity Pipeline**: By developing a ‘quadruple agonist’, Celltrion aims to leapfrog current market leaders in the obesity treatment space. This move signals a transition from a pure biosimilar player to a ‘global innovative drug developer’, potentially commanding higher valuation multiples.

2. **Open Innovation Strategy**: The expansion of its ‘open innovation’ initiatives, including the selection of new partners and plans for a UK-based hub by 2027, demonstrates a proactive approach to securing a ‘global R&D pipeline’. This collaborative model is essential for mitigating the risks associated with internal drug discovery and accelerating time-to-market for next-generation biologics.

Yuhan Corporation is currently balancing its historical legacy with significant R&D momentum as it approaches its centennial. While the unveiling of the ‘Willow House’ and the time capsule project reinforces the company’s corporate identity and long-standing reputation for integrity, the more critical driver for shareholder value is the recent progress in its pipeline expansion.

The designation of its Gaucher disease drug candidate as an Orphan Drug in both the U.S. and Europe is a major strategic milestone. This regulatory achievement not only validates the company’s global R&D competitiveness but also provides a clear pathway for accelerated commercialization and market exclusivity in the rare disease segment. This dual focus on heritage-based brand equity and high-value clinical innovation positions Yuhan for sustainable growth in its next century.

Alteogen continues to solidify its position as a global leader in drug delivery technology. The official disclosure of Sanofi as the first licensee for the ALT-B4 (hyaluronidase) platform validates the commercial viability and technological superiority of its subcutaneous (SC) conversion technology. Furthermore, the ongoing negotiations with over 10 potential partners, coupled with the anticipated milestone payments from the Keytruda SC program, provide a robust outlook for long-term revenue growth. While some market concerns regarding the composition of net income exist, the company’s fundamental value is increasingly driven by its expanding licensing-out pipeline and successful expansion into the ADC (Antibody-Drug Conjugate) therapeutic space.

The market sentiment surrounding HLB is currently dominated by the impending FDA approval decision for its liver cancer drug, Rivoceranib. The core debate centers on the CMC (Chemistry, Manufacturing, and Controls) inspection status. While the company maintains that the FDA may forgo an on-site inspection in favor of a document-based review—potentially accelerating the approval process—industry skepticism persists regarding the reliance on data from its Chinese partner, Hengrui Medicine.

Investors should note that while the absence of additional FDA requests is a positive signal, the uncertainty surrounding manufacturing quality control remains a significant regulatory risk. Furthermore, the recent volatility regarding patent issues at its subsidiary, HLB Pharmaceutical, adds a layer of operational complexity that warrants caution. The stock is currently pricing in high expectations, making it highly sensitive to any binary outcome from the FDA.